================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of report (date of earliest event reported): JUNE 30, 2003
---------------
VIVUS, INC.
- --------------------------------------------------------------------------------
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
COMMISSION FILE NUMBER: 0-23490
DELAWARE 94-3136179
- --------------------------------------------------------------------------------
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NUMBER)
1172 CASTRO STREET
MOUNTAIN VIEW, CA 94040
- --------------------------------------------------------------------------------
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
(650) 934-5200
----------------------------------------------------
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
N/A
----------------------------------------------------
(FORMER NAME, FORMER ADDRESS AND FORMER FISCAL YEAR,
IF CHANGED SINCE LAST REPORT)
================================================================================
ITEM 5. OTHER EVENTS.
On June 26, 2003, the Registrant issued a press release announcing that
data on TA-1790, an oral phosphodiesterase type 5 inhibitor for treatment of
erectile dysfunction, will be featured at the Second International Consultation
on Erectile and Sexual Dysfunction in Paris, France on June 29, 2003. The press
release is attached as exhibit 99.1 to the Current Report of Form 8-K.
EXHIBIT
NUMBER DESCRIPTION
99.1 Press Release dated June 26, 2003 announcing that data on TA-1790,
an oral phosphodiesterase type 5 inhibitor for treatment of erectile
dysfunction, will be featured at the Second International
Consultation on Erectile and Sexual Dysfunction in Paris, France on
June 29, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: June 30, 2003 VIVUS, Inc.
/s/ Richard Walliser
--------------------------------
Richard Walliser
Vice President and Chief Financial Officer
/s/ Leland F. Wilson
--------------------------------
Leland F. Wilson
President and Chief Executive Officer
VIVUS, INC.
INDEX TO EXHIBITS
The following exhibits are filed herewith:
EXHIBIT DESCRIPTION
99.1 Press Release dated June 26, 2003 announcing that data on TA-1790,
an oral phosphodiesterase type 5 inhibitor for treatment of
erectile dysfunction, will be featured at the Second International
Consultation on Erectile and Sexual Dysfunction in Paris, France
on June 29, 2003.
- ------------